IGI Logo

Caplin Point Laboratories is currently trading at Rs. 665.00, up by 9.45 points or 1.44% from its previous closing of Rs. 655.55 on the BSE.

The scrip opened at Rs. 648.15 and has touched a high and low of Rs. 673.55 and Rs. 648.15 respectively. So far 1960 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 856.00 on 02-Aug-2022 and a 52 week low of Rs. 626.30 on 11-May-2022.

Last one week high and low of the scrip stood at Rs. 679.90 and Rs. 648.15 respectively. The current market cap of the company is Rs. 5036.53 crore.

The promoters holding in the company stood at 68.80%, while Institutions and Non-Institutions held 3.36% and 27.84% respectively.

Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection, 10 mg/mL in 5 mL and 10 mL Multi-dose Vials, a generic therapeutic equivalent version of (RLD), ZEMURON Injection, of Organon USA Inc.

Rocuronium Bromide Injection is a neuromuscular blocking agent, indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. According to IQVIA (IMS Health), Rocuronium Bromide Injection had US sales of around $53 million for the 12-month period ending September 2022.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.